A. Kater

Total or free , that is the question 145

M. Kersten, A. Hagenbeek, D. M. Heijink, 2016 .

Macrophage-mediated chronic lymphocytic leukemia cell survival is independent of APRIL signaling

E. Eldering, A. Kater, S. Terpstra, 2016, Cell Death Discovery.

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation

K. Stamatopoulos, D. Rossi, G. Gaidano, 2018, Leukemia.

The APRIL paradox in normal versus malignant B cell biology

A. Kater, E. Eldering, E. Eldering, 2016, Cell Death and Disease.

Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patients

B. Lissenberg-Witte, M. V. van Gils, T. Beaumont, 2022, medRxiv.

Dichotomy in NF-κB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering

A. Kater, A. Jaspers, E. Eldering, 2010, Oncogene.

P1463: PHASE I DOSE ESCALATION OF LAVA-051, A NOVEL BISPECIFIC GAMMA-DELTA T-CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES

P. Parren, A. Broijl, P. Ghia, 2022, HemaSphere.